San Diego, CA-based medical device company Tandem Diabetes Care has filed for an IPO, which various news outlets report to be for $100 million. The number of shares and pricing terms have yet to be decided. Tandem will trade its stock on the NASDAQ under the ticker symbol “TNDM.” BofA Merrill Lynch and Piper Jaffray will act as underwriters. Tandem is backed by Delphi Ventures, Domain Associates, TPG Biotechnology Partners, HLM Venture Partners and Kearny Venture Partners.
SAN DIEGO, CA, October 07, 2013
Tandem Diabetes Care®, Inc. (“Tandem”) a medical device company and manufacturer of the t:slim® Insulin Pump, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Tandem plans to list its common stock on the NASDAQ Global Market under the ticker symbol “TNDM.”
BofA Merrill Lynch and Piper Jaffray will serve as joint book-running managers for the offering. The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus may be obtained from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038 Attention: Prospectus Department, by email at dg.Prospectus_Requests@baml.com; Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or by email at email@example.com.
A registration statement relating to the securities has been filed with the Securities and Exchange Commission, but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company manufactures and sells the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the first and only with a high resolution, color touch screen. Tandem is based in San Diego, Calif.